Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $82.0152W HIGH $156.92
Volume
9.29 M
Value Traded
783.58 M
Short % Float
1.4%
+0.9%Week
-1.31%1 Month
+17.86%3 Month
+19.91%6 Month
+60.61%5 Year
+8,098.03%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
359.22 B
EPS (TTM)
1.29
P/E Ratio
113.21
Ent. Value
401.94 B
Total Shares
2.47 B
Float Shares
2.46 B
Insiders
0.10%
Institutions
83.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MRK Catalyst Timeline
Dated clinical, regulatory and corporate events for Merck & Company, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Merck & Company, Inc.
490Total events
20Upcoming
293Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Late-BreakerTulisokibartPresentation
Tulisokibart Phase 2b HS results presented in Late-Breaking News session at EADV 2026
moderate to severe hidradenitis suppurativa (HS)source ↗
▲Secondary Endpoint DataTulisokibartClinical Data
Key secondary endpoints showed numerical improvement over placebo in Phase 2b HS trial
Moderate to severe hidradenitis suppurativa (HS)source ↗
▲Primary Endpoint MetTulisokibartClinical Data
Tulisokibart met primary endpoint of HiSCR50 at week 16 in Phase 2b HS trial
Moderate to severe hidradenitis suppurativa (HS)source ↗
●Safety Data UpdateTulisokibartClinical Data
Comparable safety profile between tulisokibart and placebo reported in Phase 2b HS trial
Moderate to severe hidradenitis suppurativa (HS)source ↗
▲Oral PresentationTulisokibartPresentation
Late-breaking oral presentation of tulisokibart Phase 2b HS data at EADV 2026
moderate to severe hidradenitis suppurativa (HS)source ↗
▲Topline ReadoutTulisokibartClinical Data
Merck presents first results from Phase 2b MK-7240-012 trial of tulisokibart in HS at EADV 2026
Moderate to severe hidradenitis suppurativa (HS)source ↗
▲Partnership / LicenseSPR2015Corporate
Merck enters exclusive global license agreement with SciBrunch for SPR2015
KRAS G12D-mutant cancers (pancreatic, colorectal, lung, and other malignant tumors)source ↗
▼BLA Submissionifinatamab deruxtecanDiscontinuedRegulatory Filing
BLA for ifinatamab deruxtecan in ES-SCLC voluntarily withdrawn
extensive-stage small cell lung cancer (ES-SCLC)source ↗
▼Drug Withdrawalifinatamab deruxtecanDiscontinuedFDA Decision
BLA for ifinatamab deruxtecan in ES-SCLC voluntarily withdrawn
extensive-stage small cell lung cancer (ES-SCLC)source ↗
▲Topline ReadoutremigromigClinical Data
Merck announces topline results from pivotal Phase 2b/3 BRUNELLO trial of remigromig in DME
diabetic macular edemasource ↗
▲Primary Endpoint MetremigromigClinical Data
Remigromig met primary endpoint of non-inferiority to ranibizumab in BCVA at week 52 in BRUNELLO
diabetic macular edemasource ↗
▼Safety Data UpdateremigromigClinical Data
Safety findings from BRUNELLO show higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and AE-related discontinuations in remigromig arms
diabetic macular edemasource ↗
▲Label ExpansionWINREVAIRApprovedFDA Decision
FDA approves label update for WINREVAIR to include Phase 3 HYPERION data in newly diagnosed PAH
Pulmonary Arterial Hypertension (PAH, WHO Group 1 Pulmonary Hypertension)source ↗
▲FDA ApprovalPembrolizumabDiscontinuedFDA Decision
Japan MHLW approves KEYTRUDA QLEX (KEYJECT) for subcutaneous use across all KEYTRUDA indications
All indications approved in Japan for KEYTRUDA (pembrolizumab)source ↗
▲CHMP Positive OpinionPembrolizumabDiscontinuedEx-US Regulatory
CHMP positive opinion for KEYTRUDA plus Padcev as perioperative treatment for resectable MIBC
resectable muscle-invasive bladder cancer (MIBC)source ↗
▲Other Regulator MilestoneWINREVAIRApprovedEx-US Regulatory
European Respiratory Society (ERS) publishes updated PAH clinical guidelines including WINREVAIR
Pulmonary Arterial Hypertension (PAH)source ↗
▲Primary Endpoint Metintismeran autogeneClinical Data
INTerpath-001 met primary endpoint of RFS and key secondary endpoint of DMFS
completely resected stage IIB-IV melanomasource ↗
▲Topline Readoutintismeran autogeneClinical Data
Positive topline results from Phase 3 INTerpath-001 trial
completely resected stage IIB-IV melanomasource ↗
▲Interim Analysisintismeran autogeneTrial
Pre-specified interim analysis showed statistically significant improvements in RFS and DMFS
completely resected stage IIB-IV melanomasource ↗
▲Partnership / LicenseCorporate
Merck and SCRI announce strategic collaboration to expand community oncology trial access via Accelero delivery model
oncologysource ↗
▲sBLA SubmissionENFLONSIAApprovedRegulatory Filing
FDA accepts sBLA for ENFLONSIA to expand indication to children under two years for second RSV season
prevention of RSV lower respiratory tract disease in children under two years at increased risk for severe RSV disease through their second RSV seasonsource ↗
▲FDA Filing AcceptedENFLONSIAApprovedRegulatory Filing
FDA accepts sBLA for ENFLONSIA to expand indication to children under two years for second RSV season
prevention of RSV lower respiratory tract disease in children under two years at increased risk for severe RSV disease through their second RSV seasonsource ↗
▲FDA ApprovalLIPFENDRAApprovedFDA Decision
FDA approval of LIPFENDRA (enlicitide) for hypercholesterolemia
Hypercholesterolemiasource ↗
▲Topline ReadoutClinical Data
Positive data from TroFuse-005 trial of sac-TMT in endometrial cancer
Advanced or recurrent endometrial cancersource ↗
▲Topline ReadoutIslatravirClinical Data
Positive Phase 3 results for once-weekly oral HIV regimen of islatravir and lenacapavir
HIVsource ↗
●Quarterly UpdatePembrolizumabDiscontinuedCorporate
KEYTRUDA/KEYTRUDA QLEX sales of $8.4 billion in Q2 2026
▲Partnership / LicenseCorporate
Evinova and Merck KGaA announce multi-year strategic collaboration
●Quarterly UpdateCorporate
Merck Board declares Q4 2026 quarterly dividend of $0.85 per share
▲Partnership / LicenseAlimatravirCorporate
Signed seven non-exclusive voluntary licensing agreements with generic manufacturers for alimatravir in 129 LMICs
HIV-1 pre-exposure prophylaxissource ↗
▲Trial InitiationAlimatravirTrial
Phase 3 EXPrESSIVE-11 trial initiated
HIV-1 pre-exposure prophylaxissource ↗
●Enrollment UpdateAlimatravirTrial
EXPrESSIVE-10 trial now enrolling
HIV-1 pre-exposure prophylaxissource ↗
▲Full ResultsAlimatravirClinical Data
Phase 2 trial results supported Phase 3 initiation
HIV-1 pre-exposure prophylaxissource ↗
▲Partnership / LicenseCorporate
Expanded clinical trial collaboration with Merck to evaluate spevatamig + KEYTRUDA + chemotherapy in 1L BTC
biliary tract cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How MRK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | tulisokibart (MK-7240-012) | Phase 2b data presentation | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A89 / 100
Pipeline Score
$62.1B
Pipeline Value
$296.9B
Commercial Value
Fair Value
Valuation Signal
138
Drugs Scored
0.6x
rNPV / MCap
Top 1%
Large Pharma(rank 1 of 658)
Percentile Rank
Merck & Company, Inc. earns an A-grade pipeline score (89/100), with $62.1B risk-adjusted pipeline value, led by MK-8527 in Human Immunodeficiency Virus (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $66.6B x 4.5 = $296.9B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Keytruda | $32.3B | $30.4B | +6.1% |
| Gardasil/Gardasil | $5.0B | $6.3B | -20.5% |
| Livestock | $4.1B | $3.7B | +12.4% |
| Companion Animal | $2.6B | $2.5B | +4.6% |
| ProQuad MMR II Varivax | $2.4B | $2.4B | -0.5% |
| Winrevair | $1.9B | $964M | +101.5% |
| Bridion | $1.9B | $1.8B | +7.7% |
| Januvia | $1.3B | $1.4B | -8.6% |
| Prevymis | $1.1B | $859M | +29.2% |
| Welireg | $886M | $598M | +48.2% |
| Capvaxive | $848M | $333M | +154.7% |
| Janumet | $820M | $958M | -14.4% |
Top 12 of 22 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8527 Small moleculeNCT07044297 | Human Immunodeficiency Virus | Phase 3 | ACTIVE NOT_RECRUITING | 9,035 | Jul 22, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every MRK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tulisokibart | moderate to severe hidradenitis suppurativa | Phase 2b | 2026-09-30 | Hi SCR50 high dose: 72%; Hi SCR50 medium dose: 64%; Hi SCR50 placebo: 35%; Hi SCR75 high dose: 41%; Hi SCR75 medium dose: 40%; Hi SCR75 low dose: 29%; Hi SCR75 placebo: 15%; DLQI high dose improvement: -5.62; DLQI medium dose improvement: -3.50; DLQI placebo improvement: -2.46Read More | Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Guindo ChirfiOfficer (EVP, Access, Policy & Comms) | Sell | -10,000 36,613.127 held | $135.00 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MRK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.6 % | 85.25 M | 663.40 K |
MRK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MRK ranks across every disease it competes in
Competitive Position is a premium feature
See how MRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMRK News
MRKMerck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Merck will conduct a conference call on October 29, 2026, to discuss its sales and earnings for the third quarter. This event aims to provide insights into the company's financial performance and future outlook. Stakeholders and investors are encouraged to participate for detailed updates.
Read more →MRKMerck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Merck announced positive results from its Phase 2b study of tulisokibart, a monoclonal antibody targeting TL1A, for treating moderate to severe hidradenitis suppurativa. The trial met both primary and key secondary endpoints, indicating the drug's potential efficacy. These findings will be presented at an upcoming event, highlighting Merck's commitment to addressing HS.
Read more →MRKMerck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor. This collaboration aims to leverage the therapeutic potential of targeting the KRAS pathway, which is significant in tumor cell growth. The agreement signifies a strategic enhancement to Merck's oncology pipeline.
Read more →MRKIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
Daiichi Sankyo and Merck have voluntarily withdrawn their Biologics License Application for ifinatamab deruxtecan, intended for treating extensive-stage small cell lung cancer. This decision follows discussions with the FDA, suggesting concerns regarding the application. The withdrawal raises questions about the future of this treatment option for patients who have progressed after chemotherapy.
Read more →MRKU.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
The U.S. FDA has approved the combination of WELIREG® (belzutifan) and LENVIMA® (lenvatinib) for adult patients with advanced renal cell carcinoma (ccRCC) who have previously been treated with PD-1/PD-L1 inhibitors. This approval is based on the Phase 3 LITESPARK-011 trial, which demonstrated significant improvements in progression-free survival. However, the overall survival did not achieve statistical significance, and there are notable safety concerns associated with the treatment.
Read more →MRKMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Merck has announced that its investigational drug remigromig has met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for adults with diabetic macular edema. This trial is significant as it is the first of two studies assessing the safety and efficacy of this novel tri-specific antibody. The results suggest a promising advancement in treatment options for DME.
Read more →MRKMerck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease
Merck Manuals has published an editorial discussing inflammatory bowel disease (IBD), detailing its symptoms, types, and treatment options. IBD, which includes Crohn disease and ulcerative colitis, can cause serious complications if untreated. The article emphasizes the importance of continuous treatment and monitoring, even during symptom-free periods, to prevent further damage.
Read more →MRKU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
Merck has announced that the U.S. FDA has approved an update to the product label for WINREVAIR (sotatercept-csrk), based on findings from the Phase 3 HYPERION trial. This update is significant for adults recently diagnosed with pulmonary arterial hypertension (PAH). The approval underscores the drug's potential in improving exercise capacity for these patients.
Read more →MRKMerck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
Merck Canada is the presenting partner for the North American premiere of Chiharu Shiota's exhibition at the Montreal Museum of Fine Arts. The exhibition features Shiota's unique thread installations and explores themes of vulnerability and hope, resonating with Merck's mission to improve lives. Additionally, Merck and the MMFA will host art and wellness initiatives for cancer-affected community groups.
Read more →MRKMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Merck has received approval from Japan's Ministry of Health for KEYTRUDA QLEX, a subcutaneous formulation of pembrolizumab. This new injection method is applicable for all indications of KEYTRUDA already approved in Japan. The product will be marketed under the name KEYJECT for subcutaneous use.
Read more →MRKMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck has received a positive opinion from the European Medicines Agency's CHMP for its drug KEYTRUDA in combination with Padcev for the treatment of adults with resectable muscle-invasive bladder cancer. This recommendation supports its use as both neoadjuvant and adjuvant therapy, indicating a significant advancement in treatment options for this patient population.
Read more →MRKMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
Merck has launched 'Your Hive of Whole Health', a multi-year educational initiative aimed at supporting individuals living with HIV. The program focuses on creating personalized support networks to enhance physical, mental, emotional, and social well-being. This initiative was introduced at the 2026 U.S. Conference on HIV/AIDS, emphasizing Merck's commitment to addressing the needs of the HIV community.
Read more →MRKMerck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Merck will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. This event is an opportunity for Merck to engage with industry leaders and showcase its contributions to healthcare. The conference is expected to attract significant attention from investors and stakeholders in the biopharma sector.
Read more →MRKMerck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Merck will participate in the Wells Fargo 21st Annual Healthcare Conference, highlighting its commitment to engaging with the investment community. This event offers an opportunity for Merck to showcase its innovations and strategies in the healthcare sector. The conference is a significant platform for networking and information exchange.
Read more →MRK▲ +12.6%on this news
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
Merck and Moderna have announced positive topline results from their Phase 3 INTerpath-001 trial. This trial evaluated the combination of intismeran autogene, an mRNA-based therapy, with KEYTRUDA® in patients with completely resected stage IIB-IV melanoma. The results indicate that the treatment met endpoints for recurrence-free survival and distant metastasis-free survival.
Read more →MRKSarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials
Sarah Cannon Research Institute has partnered with Merck to enhance access to oncology clinical trials. This collaboration will leverage SCRI's Accelero™ delivery model, which is designed to improve patient participation and streamline the trial process. The initiative aims to address barriers in accessing clinical research for oncology patients.
Read more →MRKU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
Merck has announced that the FDA has accepted a supplemental Biologics License Application for ENFLONSIA™ (clesrovimab-cfor). This application aims to expand the drug's indication to include the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in children under two years at increased risk for severe RSV disease. This is particularly relevant for their second RSV season.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Merck & Co., Inc. has announced its financial results for the second quarter of 2026, highlighting key regulatory and clinical milestones across its diverse pipeline. The announcement reflects the company's ongoing efforts to advance its portfolio and maintain transparency with stakeholders. Further details on specific milestones and financial performance were not provided in the release.
Read more →MRKMerck Announces Fourth-Quarter 2026 Dividend
Merck has announced its fourth-quarter dividend for 2026, signaling its ongoing commitment to returning value to shareholders. This decision highlights the company's financial health and stability in the current market. Investors can expect continued support through these dividend payments.
Read more →MRKBacterial Vaginosis: Merck Manuals Shares What Women and Partners Need to Know
Merck Manuals has released an editorial discussing bacterial vaginosis, a common vaginal infection. Dr. Christina Muzny provides insights on its causes, symptoms, and effective treatments. The article emphasizes the importance of professional medical advice over at-home remedies, highlighting the potential complications of untreated bacterial vaginosis and the high recurrence rates among women.
Read more →About Merck & Company, Inc.
Headquarters126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
BIOPHARMAWATCH ELITE PLUS
Trade the next MRK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime